Business Context and Reporting Period
This Form 8-K was filed by vTv Therapeutics Inc. on September 27, 2018, reporting an event that occurred on the same date. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing details a specific capital raise event rather than comprehensive financial statements. Key metrics include:
- Capital Raised: $2.5 million
- Shares Issued: 1,879,699 shares of Class A common stock
- Price Per Share: $1.33
- Investor: MacAndrews & Forbes Group LLC
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of this transaction.
Material Changes
The material change reported is the unregistered sale of equity securities. The Company exercised its right under a letter agreement dated July 30, 2018, to require the Investor to purchase the shares. This transaction increased the Company's cash position by $2.5 million and diluted existing shareholders by the issuance of approximately 1.88 million new shares.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the 2018 Letter Agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the terms of the "2018 Letter Agreement" filed as an exhibit to the subsequent Form 10-Q for the quarter ending September 30, 2018.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's cash burn rate and runway in the upcoming quarterly report to understand the utility of the $2.5 million raise.